title: "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies.
authors.affiliation: INSERM U872, Paris, France. jordan.dimitrov@crc.jussieu.fr
authors.forename: Jordan D
authors.initials: JD
authors.lastname: Dimitrov
authors.forename: Michel D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: Srinivas V
authors.initials: SV
authors.lastname: Kaveri
authors.forename: Sebastien
authors.initials: S
authors.lastname: Lacroix-Desmazes
mesh_terms: D016915:AIDS Vaccines / Q000096:biosynthesis* / Q000276:immunology; D000222:Adaptation, Physiological / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000096:biosynthesis / Q000276:immunology; D000918:Antibody Specificity; D003429:Cross Reactions / Q000276:immunology; D015195:Drug Design; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D011908:Rationalization
chemical_list: D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing